Antitrombin (AT) faolligi
Kod:3009|CPT:85300|LOINC:27811-9
| Kabi | Antitrombin faolligi |
|---|
Tahlil ma'lumotlari
Tadqiqot usuli
- Xromogen analiz
- Koagulometrik usul
Kutilayotgan natija topshirish vaqti
1 kun
Maxsus tayyorlik
- If hematocrit is greater than 55%, adjust the citrate volume in the collection tube per coagulation collection protocols.
- Infants younger than 1 year: withhold feeding for 30–40 minutes before collection.
- Children 1–5 years: fast for 2–3 hours before collection.
- Adolescents and adults: fast for 12 hours; water is allowed.
- Avoid physical and emotional stress for 30 minutes before collection.
- Do not smoke during the 30 minutes prior to collection.
Qanday foydalanish
Antitrombin (AT) faolligi testi — antitrombin III faolligi yoki geparin kofaktori faolligi deb ham ataladi — tug‘ma yoki orttirilgan antitrombin yetishmovchiligini tasdiqlash va aniqlashtirishga yordam beradi. Avvalo funksional faollik baholanadi va qiymatlar referens intervaliga to‘g‘ri keladimi-yo‘qligi aniqlanadi; so‘ng I tur (miqdoriy) va II tur (sifat jihatdan nuqsonli) ko‘rinishlarni farqlash uchun antitrombin antigeni o‘lchanadi. Ushbu test trombofiliya baholashlariga, venoz tromboembolizmning diagnostik tekshiruviga va maqsadli antikoagulyatsiyaga erishish uchun noodatiy yuqori geparin dozalarini talab etganda geparin rezistentligini aniqlashga kiritiladi.
Cheklovlar
Endotelial hujayralar va gepatotsitlar antitrombinning asosiy manbalaridir. U trombin va faollashgan Xa, IXa hamda XIa omillarini neytrallash orqali koagulyatsiyani susaytiradi va tromb hosil bo‘lishi tarqalishini cheklaydi. Irsiy antitrombin yetishmovchiligi kam uchraydi, taxminan har 5000 kishidan 1 tasida uchraydi, va takrorlanuvchi trombozga moyillikni keltirib chiqaradi; ilk hodisalar ko‘pincha erta kattalik davrida ro‘y beradi. I tur yetishmovchilik oqsil konsentratsiyasining kamayishini aks ettiradi, II tur esa antigen darajalari me’yorida bo‘lsa-da funksional nuqsonni ifodalaydi. Antitrombin faolligi shuningdek orttirilgan holatlarda kamayishi mumkin; bular qatoriga jigar disfunktsiyasi, nefrotik sindrom, disseminatsiyalangan tomir ichi ivish (DIC), katta jarrohlik amaliyoti, keng tromboz, katta qon yo‘qotish, malignitet, geparinga uzoq muddatli ta’sir va og‘iz orqali qabul qilinadigan kontraseptivlarning yuqori dozalari kiradi. Klinik jihatdan, yetarli bo‘lmagan antitrombin takrorlanuvchi venoz va arterial trombotik hodisalar bilan bog‘liq; irsiy yetishmovchilikda miokard infarkti va insult erta yoshda yuz berishi mumkin.
| O'lchov birligi | % | ||||
|---|---|---|---|---|---|
| Referens oraliq |
| ||||
| Ko'rsatmalar | Thrombophilia assessment alongside protein C, protein S, and lupus anticoagulant studies., Evaluation of patients with suspected or confirmed venous thromboembolism., Follow-up testing after thrombectomy., Workup of suspected heparin resistance, defined by the need for high-dose heparin to reach therapeutic anticoagulation. |
Natija og'ishlarining mumkin sabablari
Oshgan daraja
- direct xa inhibitors
- warfarin
Pasaygan daraja
- unfractionated heparin
Namunangiz talablari
| Namunangiz | Plazma |
|---|---|
| Container | Och ko'k qopqoqli probirka (3,2% natriy sitrat) |
| Hajm | 1 mL |
| Saqlash tayyorlik | Muzlatilgan |
References
Khor B, Van Cott EM. Laboratory tests for antithrombin deficiency. Am J Hematol. 2010 Dec;85(12):947-950.
Moore GW. Thrombophilia Screening: Not So Straightforward. Semin Thromb Hemost. 2024 Nov;50(8):1131-1152.
STA Stachrom AT III Instructions for Use (package insert). October 2018.